Table 3.
UN regions | Scenarios | Cases (thousands) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Pharyngitis | Impetigo | Invasive disease | Cellulitis | Rheumatic heart disease | |||||||
South Asia | 1,2,5,6 | 997,239 | 1,992,706 | 139,217 | 211,562 | 612 | 728 | 7642 | 14,792 | 2893 | 10,741 |
3,4 | 1,014,494 | 2,027,050 | 141,670 | 215,255 | 623 | 741 | 7777 | 15,050 | 2939 | 10,907 | |
Europe & Central Asia | 1,2,5,6 | 316,919 | 633,687 | 44,127 | 67,156 | 193 | 230 | 3747 | 7211 | 249 | 654 |
3,4 | 322,505 | 644,834 | 44,909 | 68,342 | 196 | 234 | 3805 | 7324 | 249 | 654 | |
Middle East & North Africa | 1,2,5,6 | 314,558 | 628,787 | 43,838 | 66,679 | 192 | 229 | 2345 | 4266 | 928 | 2454 |
3,4 | 312,173 | 623,985 | 43,514 | 66,179 | 190 | 227 | 2330 | 4238 | 916 | 2422 | |
Sub-Saharan Africa | 1,2,5,6 | 1,517,327 | 3,025,939 | 212,901 | 322,443 | 942 | 1118 | 12,223 | 22,891 | 10,967 | 32,735 |
3,4 | 1,449,400 | 2,889,696 | 203,532 | 308,103 | 901 | 1070 | 11,673 | 21,846 | 10,478 | 31,289 | |
Latin America & Caribbean | 1,2,5,6 | 286,031 | 571,793 | 39,855 | 60,626 | 174 | 208 | 7949 | 11,387 | 1163 | 3235 |
3,4 | 297,851 | 595,385 | 41,511 | 63,136 | 182 | 216 | 8308 | 11,895 | 1204 | 3350 | |
East Asia & Pacific | 1,2,5,6 | 831,037 | 1,661,287 | 115,783 | 176,134 | 506 | 603 | 6386 | 10,512 | 1970 | 4811 |
3,4 | 862,246 | 1,723,558 | 120,157 | 182,764 | 525 | 626 | 6626 | 10,902 | 2038 | 4980 | |
North America | 1,2,5,6 | 150,714 | 301,372 | 20,984 | 31,937 | 92 | 109 | 7568 | 16,919 | 9 | 16 |
3,4 | 150,087 | 300,114 | 20,898 | 31,805 | 91 | 109 | 7538 | 16,851 | 9 | 16 | |
Global | 1,2,5,6 | 4,413,825 | 8,815,571 | 616,705 | 936,537 | 2709 | 3224 | 47,860 | 87,977 | 18,179 | 54,646 |
3,4 | 4,408,757 | 8,804,622 | 616,192 | 935,583 | 2709 | 3223 | 48,057 | 88,105 | 17,833 | 53,619 |
The baseline cases (pre-vaccination) of Strep A disease burden (pharyngitis, impetigo, invasive disease, cellulitis, and rheumatic heart disease) is presented at the regional (United Nations regions) and global levels, based on 30 birth cohorts from year of vaccine introduction and for duration associated with the vaccination scenarios. Case numbers are split between those scenarios that have country-specific years of introduction (1,2,5,6) and those introduced in 2022 (3,4). The left column of case numbers relate to the 10-year durability assumption and the right column to 20-year durability of vaccine protection.